Nanoscale coatings for ultralow dose BMP-2-driven regeneration of critical-sized bone defects

Zhe A. Cheng, Andres Alba-Perez, Cristina Gonzalez-Garcia, Hannah Donnelly, Virginia Llopis-Hernandez, Vineetha Jayawarna, Peter Childs, David W. Shields, Marco Cantini, Laura Ruiz-Cantu, Andrew Reid, James F. C. Windmill, Elena S. Addison, Sandra Corr, William G. Marshall, Matthew J. Dalby, Manuel Salmeron-Sanchez

Research output: Contribution to journalArticlepeer-review

53 Citations (Scopus)
46 Downloads (Pure)


While new biomaterials for regenerative therapies are being reported in the literature, clinical translation is slow. Some existing regenerative approaches rely on high doses of growth factors, such as bone morphogenetic protein-2 (BMP-2) in bone regeneration, which can cause serious side effects. An ultralow-dose growth factor technology is described yielding high bioactivity based on a simple polymer, poly(ethyl acrylate) (PEA), and report mechanisms to drive stem cell differentiation and bone regeneration in a critical-sized murine defect model with translation to a clinical veterinary setting. This material-based technology triggers spontaneous fibronectin organization and stimulates growth factor signalling, enabling synergistic integrin and BMP-2 receptor activation in mesenchymal stem cells. To translate this technology, for the first time, plasma-polymerized PEA is used on 2D and 3D substrates to enhance cell signalling in vitro, showing the complete healing of a critical sized bone injury in mice in vivo. Efficacy is demonstrated in a Münsterländer dog with a nonhealing humerus fracture, establishing the clinical translation of advanced ultralow-dose growth factor treatment.
Original languageEnglish
Article number1800361
Number of pages12
JournalAdvanced Science
Issue number2
Early online date19 Nov 2018
Publication statusPublished - 23 Jan 2019


  • biomaterials
  • bone regeneration
  • growth factor delivery
  • stem cell differentiation


Dive into the research topics of 'Nanoscale coatings for ultralow dose BMP-2-driven regeneration of critical-sized bone defects'. Together they form a unique fingerprint.

Cite this